Analytical Data
-
Gene name
LILRA1/LIR-6/CD85i
-
简介
LILRA1/LIR-6/CD85i protein serves as a receptor for class I MHC antigens and plays a crucial role in immune recognition and response. Its interaction with class I MHC molecules suggests involvement in monitoring and possibly influencing immune activity. LILRA1/LIR-6/CD85i Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LILRA1/LIR-6/CD85i protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
Alternative Names
CD85i; LILRA1; LIR6; LIR-6; LIR6MGC126563
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75019-1
-
Expression Region
P17-N461
-
Protein Length
Extracellular Domain
-
Molecular Weight
70-80 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRA1, also known as LIR-6 or CD85i, is a member of the leukocyte immunoglobulin-like receptor (LIR) family, playing a crucial role in the immune system's regulation. It is predominantly expressed on immune cells, including monocytes and dendritic cells, and is involved in modulating immune responses by recognizing specific ligands. Research has indicated that LILRA1 can influence various processes such as cell activation, cytokine production, and antigen presentation, thereby affecting adaptive and innate immunity. The study of LILRA1 is particularly significant in understanding its potential implications in autoimmune diseases, infectious diseases, and cancer immunotherapy. Its ability to regulate immune cell interactions and function makes it an attractive target for developing therapeutic interventions. Moreover, recombinant proteins of LILRA1 can be utilized in experimental settings to further elucidate its biological functions, binding characteristics, and signaling pathways, contributing to a deeper understanding of immune regulation mechanisms. Investigating LILRA1/LIR-6/CD85i not only enhances our comprehension of immune cell dynamics but also paves the way for novel immunotherapeutic strategies that could improve patient outcomes in various diseases.
